Genomate Health

06/04/2026

Precision oncology doesn't stop at sequencing.

As part of the BRECISE project, Genomate analyzed bladder cancer patient cohorts from Erasmus MC to identify targeted therapy candidates for ex vivo validation using our computational reasoning platform.

The goal: move beyond individual mutations and understand the complete molecular context of each tumor to uncover more precise treatment opportunities. A great example of how computational reasoning can help translate molecular complexity into actionable therapeutic insights.

Barbara Vodicska, PhD, shares more about this milestone and what's next for the project: https://www.youtube.com/watch?v=ulyagBSLnP8

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

06/02/2026

We can sequence tumors at scale.
But interpreting increasingly complex molecular profiles, often involving multiple driver alterations in most cases, remains a major challenge.

At , we’ve presented an analysis of 20,923 patients from the MSK-CHORD clinicogenomic dataset, exploring the clinical utility of Genomate®, our computational reasoning system.

Our findings showed:
• 75% of tumors were associated with at least one high-scored* molecularly targeted therapy option
• Yet only 37% of patients received such targeted therapy during the whole course of their treatment, and only 26.5% among patients right after the NGS testing
• Tumors contained an average of 4.6 driver alterations, highlighting the growing complexity of molecular decision-making

The results underscore an important reality in modern oncology: the challenge is no longer only generating genomic data, but interpreting the full molecular context to guide treatment decisions at scale.

Breakdown of the results here: https://lnkd.in/dn4qkq4a
Full abstract: https://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17086?presentation=263141

Dóra Lakatos PhD, Robert Doczi, PhD, Mária Kocsis-Steinbach, Kalmar Gabor, Anna Dirner, Enikő Kispéter, Dóra Görög-Tihanyi, Barbara Vodicska, PhD, William T Beck, Istvan Petak MD, PhD



* Previous research evidenced that MTAs assigned with a high Genomate score provide increased clinical benefit (NPJ Precis Oncol. 2021 5:59; NPJ Precis Oncol. 2025 9:159).

05/31/2026

Cancer care is full of difficult decisions.
What treatment is right?
What happens next?
Is there another option?
These are questions many patients are forced to face, often under pressure, often without certainty.

Prevention is different. Smoking is linked to up to 1 in 3 cancer deaths, making it one of the most preventable risk factors.

World No To***co Day is a reminder that some of the most important choices happen long before a diagnosis, when they can still change what comes next.
Because the best cancer decision is sometimes the one you never have to make.

***coDay

05/29/2026

Brain tumors are among the most complex cancers. Not just because of what they are, but because of where they are. A tumor’s location can limit treatment options. Its biology can change how it behaves. And even small differences can lead to very different outcomes.

That means every decision carries weight. And uncertainty is often part of the process.

At Genomate Health, we focus on understanding that complexity, looking beyond isolated findings to see how everything connects within a patient’s cancer.

Because when the full picture becomes clearer, so do the decisions: https://bit.ly/3RBiN8w

05/28/2026

Heading to ? Let’s meet!

Dóra Lakatos PhD, Head of Computational Science at Genomate Health, and Julia Deri, Precision Oncology Specialist at Oncompass Medicine, a Genomate Health company, will be there to present our latest research on computational reasoning and large-scale tumor genomic data.
If you’ll be at ASCO and would like to connect, let us know. We’re excited to meet clinicians, researchers, partners, and innovators who are thinking about the future of precision oncology, real-world evidence, and computational approaches to cancer care.

Our latest study explores how computational reasoning applied to large-scale real-world tumor genomic data may help uncover treatment opportunities that are often difficult to identify using conventional biomarker-focused approaches.

Clinical utility analysis of a computational reasoning system on large-scale tumor genomic data
Authors: Dóra Lakatos PhD, Robert Doczi, PhD, Mária Kocsis-Steinbach, Kalmar Gabor, Anna Dirner, Enikő Kispéter, Dóra Görög-Tihanyi, Barbara Vodicska, PhD, William T Beck, Istvan Petak MD, PhD

📍 Abstract 1625 | Poster Board 543
Track: Care Delivery / Models of Care (Hall A)
May 30, 2026, 9:00 - 12:00 PM CDT
Full abstract: https://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17086?presentation=263141
Breakdown of the results here: https://www.genomate.health/publication/genomate-clinical-utility-analysis-msk-chord-large-scale-tumor-genomic-data

05/26/2026

What can we learn when computational reasoning is applied to one of the world’s largest real-world clinicogenomic cancer datasets?

At , Genomate Health will present new research analyzing 20,923 patient tumor profiles from the MSK-CHORD real-world clinicogenomic dataset (Nature). Using Genomate®, our computational reasoning system, the study explored how whole-profile molecular interpretation can uncover clinically meaningful treatment opportunities that may be missed by reductionist approaches focused on single biomarkers alone.

The findings revealed a significant gap between the number of patients whose tumor profiles were associated with high-score targeted therapy options — defined as therapies strongly supported by Genomate’s computational reasoning analysis* — and the number of patients who actually received those therapies in clinical practice.

Why does this matter?

Because cancer is molecularly complex.And computational interpretation of the full (molecular) context of a tumor may be essential for improving precision oncology decision-making and making it scalable. We broke down the results here: https://www.genomate.health/publication/genomate-clinical-utility-analysis-msk-chord-large-scale-tumor-genomic-data

📍 Abstract 1625 | Poster Board 543
Track: Care Delivery / Models of Care (Hall A)
May 30, 2026, 9:00 - 12:00 PM CDT
Read the full abstract: https://meetings.asco.org/meetings/2026-asco-annual-meeting/335/17086?presentation=263141
Authors: Dóra Lakatos PhD, Robert Doczi, PhD, Mária Kocsis-Steinbach, Kalmar Gabor, Anna Dirner, Enikő Kispéter, Dóra Görög-Tihanyi, Barbara Vodicska, PhD, William T Beck, Istvan Petak MD, PhD



* Previous research evidenced that MTAs assigned with a high Genomate score provide increased clinical benefit (NPJ Precis Oncol. 2021 5:59; NPJ Precis Oncol. 2025 9:159)

05/21/2026

Today, two people might hear the same words: “You have bladder cancer.”
But from that moment on, their stories may completely diverge.

One responds to treatment.
One doesn’t.
One gains time.
One runs out of options.

Not because the diagnosis was wrong, but because cancer is far more individual the organ it originates from. Behind every tumor is a unique biological system: different drivers, different interactions, different vulnerabilities. What appears identical on paper can behave very differently in real life.

At Genomate Health, we believe precision oncology must go beyond isolated biomarkers and one-size-fits-all interpretation. Our computational reasoning approach helps reveal the full complexity of each patient’s cancer, connecting molecular evidence into clinically meaningful understanding.

This Bladder Cancer Awareness Month we're highlighting an important truth: precision medicine begins with understanding the whole cancer, not just where it started.

If you or a loved one is facing bladder cancer, you can learn more about how our Second Opinion can offer more clarity: https://bit.ly/49cgWwJ

05/15/2026

A cancer diagnosis doesn’t only affect the body, it affects the mind too.
The uncertainty, the second-guessing, the fear of making the wrong decision… these can weigh heavily on patients and families long after diagnosis.

During , we want to recognize that emotional clarity matters just as much as clinical clarity.

At Genomate Health, our Second Opinion service is designed to help patients better understand the full picture of their cancer, explore potential treatment options, and feel more confident about what comes next: https://shorturl.at/Kyoq5

Because sometimes, peace of mind begins with knowing you’re on the right path.

05/13/2026

Cancer research has advanced at an incredible pace.
More data.
More discoveries.
More possibilities than ever before.
And yet, for many patients, the hardest question remains: What is the right decision?

This May, during Cancer Research Month, the American Association for Cancer Research® (AACR) is bringing together the global oncology community to celebrate the extraordinary progress made possible through cancer research, and to highlight the urgent need to accelerate it further.

At Genomate Health, we are proud to contribute to this momentum by helping transform growing scientific complexity into clinically meaningful insight. Using computational reasoning, we connect molecular biology, scientific evidence, and clinical context to support more informed, patient-specific treatment decisions.

This year at , our team presented three studies highlighting the clinical and translational potential of computational reasoning in oncology:
• Molecularly informed prediction of treatment efficacy in GDSC cell line data using computational reasoning
• Molecularly-informed prediction of treatment efficacy in the GENIE BPC NSCLC cohort using computational reasoning
• Clinical efficacy of computational reasoning for personalized treatment planning in a pan-cancer cohort discussed by a French multidisciplinary tumour board: a real-world experience-based analysis

These advances are also helping bring more personalized, research-driven insights closer to patients through our computational reasoning-powered Second Opinion Service, designed to help patients and oncologists better understand the full molecular complexity of each cancer case: https://www.genomate.health/services/second-opinion

We are also looking forward to continuing the conversation at , where we will present additional research focused on advancing precision oncology and helping clinicians benefit from the full pace of cancer science.

Because the future of cancer care depends not only on discovering more, but on understanding more.

05/08/2026

On average, women wait 31 weeks, from first noticing symptoms to receiving an ovarian cancer diagnosis.

That’s not because symptoms don’t exist. It’s because they’re often missed, misunderstood, or dismissed. And by the time a diagnosis is made, the disease is often already advanced.

This is why this year’s World Ovarian Cancer Coalition call theme matters:
No woman’s symptoms should be ignored.
No woman should face delays in diagnosis.
No woman should be left navigating uncertainty alone.

Ovarian cancer isn’t just hard to detect, it’s hard to interpret early.

And that gap costs time.
Time that patients don’t have.